Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins

Vaccine

Volumn 17, Issue 20-21, 1999, Pages 2612-2619

  Cartwright, Keith ^a   Morris, Rhonwen ^a   Rümke, Hans ^b   Fox, Andrew ^c   Ray Borrow, ^c   Begg, Norman ^d   Richmond, Peter ^d   Poolman, Jan ^b  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c WITHINGTON HOSPITAL   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Infants; Meningococcal vaccine; PorA

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MENINGOCOCCEMIA; NORMAL HUMAN; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT OUTCOME; UNITED KINGDOM; VACCINATION;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; FEMALE; HUMANS; INFANT; MALE; NEISSERIA MENINGITIDIS; PORINS; VACCINES, SYNTHETIC;

EID: 0033523057     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00044-4     Document Type: Article

References (33)

1. Kaczmarski E.B. Meningococcal disease in England and Wales: 1995. Commun Dis Rep Rev. 7:1997;R55-9.
2. Fortnum H., Mason K. Reliability of notification data for childhood bacterial meningitis. J Public Health Med. 15:1993;315-319.
3. Ramsay M., Kaczmarski E., Rush M., Mallard R., Farrington P., White J. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep Rev. 7:1997;R49-54.
4. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 129:1969;1307-1326.
5. Fairley C.K., Begg N., Borrow R., Fox A.J., Jones D.M., Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis. 174:1996;1360-1363.
6. Wyle F.A., Artenstein M.S., Brandt B.L.et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 126:1972;514-522.
7. Finne J.M., Leinonen M., Mäkelä P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development. Lancet. ii:1983;355-357.
8. Frasch C.E., Chapman S.S. Classification of Neisseria meningitidis serogroup B into distinct serotypes. III. Application of a new bactericidal inhibition technique to distribution of serotypes among cases and carriers. J Infect Dis. 127:1973;149-154.
9. Jones D.M., Eldridge J. Development of antibodies to meningococcal protein and lipopolysaccharide antigens in healthy carriers. J Med Microbiol. 12:1979;107-111.
10. Griffiss J.M., Brandt B.L., Broud D.D., Goroff D.K., Baker C.J. Immune responses of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis. 150:1984;71-79.
11. Bjune G., Hoiby E.A., Gronnesby J.K.et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 338:1991;1093-1096.
12. Sierra G.V.G., Campa H.C., Varcacel N.W.et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:1991;195-207.
13. de Moraes J.C., Perkins B., Camargo M.C.et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 340:1992;1074-1078.
14. Boslego J., Garcia J., Cruz C.et al. Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine. 13:1995;821-829.
15. Rosenqvist E., Hoiby E.A., Wedege E.et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun. 63:1995;4642-4652.
16. Zollinger W.D., Boslego J., Moran E.et al. Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH Ann. 14:1991;211-213.
17. Milagres L.G., Ramos S.R., Sacchi C.T.et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 62:1994;4419-4424.
18. van der Ley P.A., Heckels J.E., Virji M., Hoogerhout P., Poolman J.T. Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun. 59:1990;2963-2971.
19. Poolman J.T., van der Ley P.A., Tommassen J. Surface structures of meningococci. Cartwright K., Meningococcal disease. 1995;21-34 John Wiley and Sons, Chichester.
20. Saukkonen K., Leinonen M., Abdillahi H., Poolman J.T. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine. 7:1989;325-328.
21. Poolman J.T. Clinical trials with outer membrane protein vaccines and porA recombinant vaccines. Zollinger W.D., Frasch C.E., Deal C.D., Pathogenic Neisseria. Abstracts of the 10th International Pathogenic Neisseria Conference, Baltimore, MD. 1996;117-122 National Institutes of Health, Bethesda.
22. Poolman J.T., de Marie S., Zanen H.C. Variability of low-molecular weight, heat-modifiable outer membrane proteins of Neisseria meningitidis. Infect Immun. 30:1980;642-648.
23. Woods J.P., Cannon J.G. Variation in expression of class 1 and class 5 outer membrane proteins during nasopharyngeal carriage of Neisseria meningitidis. Infect Immun. 58:1990;569-572.
24. van der Ley P.A., van der Biezen J., Poolman J.T. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of multivalent outer membrane vesicle vaccine. Vaccine. 13:1995;401-407.
25. Rouppe van der Voort E., van der Ley P., van der Biezen J.et al. Specificity of human bactericidal antibodies against porA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun. 64:1996;2745-2751.
26. Claassen I., Meylis J., van der Ley P.et al. Production, characterisation and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine. 14:1996;1001-1008.
27. Peeters C.C.A.M., Rümke H.C., Sundermann L.C.et al. Phase 1 clinical trial with a hexavalent PorA-containing meningococcal outer membrane vesicle vaccine. Vaccine. 10:1996;1009-1015.
28. Department of Health, Welsh Office, Scottish Home and Health Department. Immunisation against infectious disease. 2nd ed. 1992;54 HMSO, London.
29. Department of Health, Welsh Office, Scottish Home and Health Department. Immunisation against infectious disease. 2nd ed. 1992;10 HMSO, London.
30. Centers for Disease Control. Report of the 2nd International Workshop on meningococcal immunology and serology, 17-18 June 1992 (Decatur, GA). Atlanta: CDC, 1992.
31. Goldblatt D., Fairley C.K., Cartwright K., Miller E. Interchangeability of conjugated Haemophilus influenzae type b vaccines during the primary immunisation of infants at 2, 3 and 4 months. Br Med J. 312:1996;817-818.
32. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 129:1969;1327-1348.
33. Jones D.M., Mallard R.H. Age incidence of meningococcal infection, England and Wales 1984-1991. J Infect. 27:1993;83-88.